group IVC sPLA2 Inhibitors
Group IVC sPLA2 Inhibitors encompass a class of compounds that indirectly inhibit the enzymatic activity of group IVC sPLA2. This enzyme is responsible for hydrolyzing membrane phospholipids to release arachidonic acid, which is then converted into various eicosanoids, including prostaglandins and leukotrienes, through the action of COX and lipoxygenase enzymes. Compounds like indomethacin, rofecoxib, aspirin, ibuprofen, and naproxen function as nonselective COX inhibitors or, in the case of rofecoxib, celecoxib, meloxicam, nimesulide, valdecoxib, and etoricoxib, as selective COX-2 inhibitors. By inhibiting COX enzymes, these compounds reduce the synthesis of prostaglandins. With a lower demand for prostaglandins, the need for arachidonic acid is reduced, which in turn can lead to a decrease in the activity of group IVC sPLA2 as there is less substrate requirement for its action.
Licofelone is unique as it inhibits both COX and 5-lipoxygenase (5-LOX), affecting both prostaglandin and leukotriene pathways. By simultaneously diminishing the levels of these eicosanoids, licofelone could decrease the functional activity of group IVC sPLA2 by significantly reducing the need for its activity in releasing arachidonic acid. Bromfenac, while primarily known as an NSAID withCOX inhibitory action, can also decrease prostaglandin levels, leading to a similar reduction in group IVC sPLA2 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
A nonselective COX inhibitor that reduces the production of prostaglandins, downstream products of arachidonic acid released by group IVC sPLA2 activity, thus indirectly inhibiting group IVC sPLA2 by reducing the demand for its substrate. | ||||||
Vioxx | 162011-90-7 | sc-208486 | 100 mg | $190.00 | 3 | |
A selective COX-2 inhibitor that decreases prostaglandin synthesis specifically during inflammation, indirectly reducing group IVC sPLA2 activity by lowering substrate utilization in the inflammatory response. | ||||||
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $42.00 | 4 | |
Acetylates and irreversibly inhibits COX enzymes, which decreases prostaglandin production and may reduce the functional activity of group IVC sPLA2 by diminishing the need for arachidonic acid liberation. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $53.00 $88.00 | 6 | |
A nonselective COX inhibitor that lessens prostaglandin synthesis, potentially decreasing group IVC sPLA2 activity indirectly by reducing the utilization of its arachidonic acid product. | ||||||
Naproxen | 22204-53-1 | sc-200506 sc-200506A | 1 g 5 g | $24.00 $41.00 | ||
Another nonselective COX inhibitor, naproxen lowers prostaglandin production, which could lead to reduced group IVC sPLA2 activity by minimizing the demand for arachidonic acid release. | ||||||
Meloxicam | 71125-38-7 | sc-200626 sc-200626A sc-200626B | 20 mg 100 mg 500 mg | $36.00 $94.00 $156.00 | 3 | |
Preferentially inhibits COX-2, leading to reduced prostaglandin production and potentially less demand for arachidonic acid, thus indirectly inhibiting group IVC sPLA2. | ||||||
Nimesulide | 51803-78-2 | sc-200623 | 5 g | $72.00 | 1 | |
Preferentially inhibits COX-2 and could decrease the production of prostaglandins, potentially reducing group IVC sPLA2 activity by lowering the need for arachidonic acid release. | ||||||
Etoricoxib | 202409-33-4 | sc-218446 | 10 mg | $36.00 | 3 | |
Selectively inhibits COX-2, reducing prostaglandin production and potentially diminishing the functional activity of group IVC sPLA2 through decreased substrate utilization. | ||||||